INBRAIN Neuroelectronics, a company developing graphene-based brain-computer interface therapeutics, announced the appointment of Scott Huennekens as Chairman of its Board of Directors. Huennekens joins the company as INBRAIN advances its next-generation BCI therapeutics toward pivotal clinical trials and commercialization for neurological disorders.
Health Technology Insights: University of Rochester Medical Center and GE HealthCare Launch 7-Year Care Alliance
Carolina Aguilar, CEO and Co-Founder of INBRAIN Neuroelectronics, said that Huennekens brings a remarkable record of scaling medtech companies and guiding them through critical growth stages. She emphasized that his leadership experience across imaging, surgical robotics, and intelligent device platforms will be essential as INBRAIN progresses its precision BCI therapeutics into later-stage development. Aguilar expressed excitement in welcoming him as Chairman at a defining moment for the company.
Health Technology Insights: AI Governance in Drug Safety: Lessons from IQVIA
Huennekens is an accomplished medtech executive, entrepreneur, and board member with more than twenty years of experience founding, growing, and advising category-leading healthcare technology companies. Over his career, he has served as the CEO of two unicorn-valued start-ups and contributed to more than ten high-growth medtech companies with combined valuations exceeding six billion dollars, helping deliver technologies that have impacted over twenty million patients worldwide.
Most recently, Huennekens served as President and CEO of Verb Surgical, the joint venture between Google and Johnson & Johnson focused on expanding access to surgery through robotics, AI, advanced visualization, and data-driven insights. Before that, he was the founding President and CEO of Volcano Corporation, leading the company from inception to an IPO and eventual acquisition by Philips. Under his leadership, Volcano became a global leader in image-guided therapy, achieving annual revenue above four hundred million dollars and a peak market capitalization nearing two billion dollars. Earlier, he served as President and CEO of Digirad Corporation, which went public on Nasdaq.
Huennekens said he is impressed by INBRAIN’s BCI therapeutic platform and believes graphene offers unmatched precision, biocompatibility, and signal quality that could enable safer and more personalized neuroelectronic treatments. He expressed enthusiasm for supporting Aguilar and the team in scaling the technology to bring a new generation of neurotherapeutics to patients with neurological disorders.
Huennekens currently serves on the boards of NeuroPace, QuidelOrtho, Envista, Elucid, and Kardion and previously chaired the Medical Device Manufacturers Association. He holds a degree from the University of Southern California and an MBA from Harvard Business School.
Health Technology Insights: GE HealthCare Launches Imaging 360 Powered By AI to Improve Operations Efficiency
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
